Abstract: Polypeptides for use in vaccines against influenza are described. The polypeptides comprise a haemagglutinin subtype 5 (H5) globular head domain, and optionally a haemagglutinin stem domain, with the following amino acid residues at positions 156, 157, 171, 172, and 205 of the head domain: •156: R; •157: P or S, preferably P; •171: D or N; •172: T or A, preferably T; and •205: K or R, preferably K Nucleic acid molecules encoding the polypeptides, vectors, cells, fusion proteins, and pharmaceutical compositions are also described.

Abstract: Methods for identifying optimized antigenic pathogen polypeptides capable of inducing a broadly neutralizing immune response, and associated T-cell responses, to a pathogen are described, as well as nucleic acid sequences encoding such polypeptides. Methods for determining whether a broadly neutralizing immune response is induced in a subject following immunization with an optimized antigenic pathogen polypeptide, or a nucleic acid encoding the optimized pathogen polypeptide, are also described. Nucleic acid molecules, polypeptides, vectors, cells, fusion proteins, pharmaceutical compositions, and their use as vaccines against pathogens, especially against emerging or re-emerging pathogens (particularly RNA viruses), are also described.

Abstract: The present invention concerns liquid nutritional compositions comprising at least about 20% (w/w) total protein, and wherein the total protein essentially comprises whey protein and casein. The Compositions are useful for promoting muscle growth in a subject.

Abstract: The present invention relates to food products comprising potassium salts, and has as an object to provide a food product enriched in potassium which helps in reduction of blood pressure, however without the bitter taste associated with increased potassium levels. The invention provides a beverage comprising potassium at a total concentration between 3 and 15 gram potassium per liter, and locust bean gum.

Abstract: A large number of recombinant of viral and bacterial systems has been engineered as vectors to express foreign genes for vaccination and/or gene therapy. A common problem is the immune response to the vector itself. The presence of anti-vector immune response may preclude sufficient priming or delivery if pre-existing immune responses are present, or impair optimal “boosting” upon subsequent immunisation or delivery. The invention provides means and methods for vaccinating an animal or a human to obtain therein an immune response against at least one antigen, comprising different vaccine compositions for sequential administration to said animal or said human, each containing at least said antigen or a precursor thereof, wherein said vaccine compositions differ from each other by the presence therein of a different vector.